SNZZF Stock - Senzime AB (publ)
Unlock GoAI Insights for SNZZF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $58.48M | $35.75M | $14.03M | $10.98M | $9.34M |
| Gross Profit | $20.12M | $8.34M | $-4,395,000 | $-4,923,000 | $-7,899,000 |
| Gross Margin | 34.4% | 23.3% | -31.3% | -44.8% | -84.6% |
| Operating Income | $-124,054,000 | $-137,360,000 | $-133,905,000 | $-84,191,000 | $-48,866,000 |
| Net Income | $-118,727,000 | $-134,149,000 | $-132,700,000 | $-82,143,000 | $-47,444,000 |
| Net Margin | -203.0% | -375.2% | -945.6% | -748.1% | -508.1% |
| EPS | $-0.95 | $-1.45 | $-1.96 | $-1.30 | $-0.83 |
Senzime AB (publ), a medical device company, develops and markets patient monitoring systems to monitor patients under anesthesia in Europe, Oceania, Asia, Canada, and the United States. The company offers TetraGraph, a monitor that stimulates, measures, analyzes, and displays muscle function in surgical patients receiving neuromuscular blocking agents; TetraSens electrode array, which has two proximal stimulating electrodes for recording and reference; TetraConnect, a data management portal that helps clinician to access, view, and export data records from the TetraGraph in PDF or Excel format; TetraGraph Device Connectivity, which transfers data from the TetraGraph Monitor to patient monitoring systems; and TetraGraph Philips Interface that enables the transmission of neuromuscular monitoring parameters, TOFC, TOFR, PTC, and TOF bars to Philips patient monitors, as well as TetraGraph readings are displayed on the Philips Intellivue Monitor. It also develops CliniSenz Analyzer for postoperative and continuous patient monitoring in hospital environments; and Onzurf Probe, a sterile CE-marked single use product based on micro-dialysis technology that enables continuous sampling from gastro-intestinal organs, such as esophagus, stomach, and liver. Senzime AB (publ) has a strategic license and connectivity agreement with Masimo to develop and market the TetraGraph Smart Cable Module that connects directly to Root monitoring system, as well as to their digital hubs to interface with the hospital clinical information system/electronic health records. The company was incorporated in 1999 and is based in Uppsala, Sweden.
Visit WebsiteEarnings History & Surprises
SNZZFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 20, 2026 | — | — | — | — |
Q1 2026 | Feb 16, 2026 | — | — | — | — |
Q4 2025 | Oct 29, 2025 | $-0.01 | $-0.00 | +85.5% | ✓ BEAT |
Q3 2025 | Aug 29, 2025 | $-0.02 | $-0.03 | -42.6% | ✗ MISS |
Q2 2025 | Apr 22, 2025 | $-0.02 | $-0.03 | -9.2% | ✗ MISS |
Q1 2025 | Feb 17, 2025 | $-0.02 | $-0.02 | -0.2% | ✗ MISS |
Q4 2024 | Nov 6, 2024 | $-0.02 | $-0.03 | -11.8% | ✗ MISS |
Q3 2024 | Aug 26, 2024 | $-0.02 | $-0.03 | -40.6% | ✗ MISS |
Q2 2024 | May 7, 2024 | $-0.03 | $-0.02 | +23.2% | ✓ BEAT |
Q1 2024 | Feb 15, 2024 | $-0.03 | $-0.03 | -8.9% | ✗ MISS |
Q3 2023 | Sep 30, 2023 | $-0.03 | $-0.03 | -9.3% | ✗ MISS |
Q2 2023 | Jun 30, 2023 | $-0.03 | $-0.04 | -25.9% | ✗ MISS |
Q1 2023 | Mar 31, 2023 | — | $-0.04 | — | — |
Q1 2023 | Feb 1, 2023 | — | $-0.03 | — | — |
Q4 2022 | Nov 10, 2022 | — | $-0.07 | — | — |
Q3 2022 | Jul 15, 2022 | — | $-0.06 | — | — |
Q2 2022 | May 5, 2022 | — | $-0.03 | — | — |
Q1 2022 | Feb 17, 2022 | — | $-0.04 | — | — |
Q4 2021 | Nov 12, 2021 | — | $-0.03 | — | — |
Q3 2021 | Aug 27, 2021 | — | $-0.04 | — | — |
Latest News
Frequently Asked Questions about SNZZF
What is SNZZF's current stock price?
What is the analyst price target for SNZZF?
What sector is Senzime AB (publ) in?
What is SNZZF's market cap?
Does SNZZF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to SNZZF for comparison